Evidence map›Paper›PMID 37100206›Full record

ReviewAdvanced drug delivery reviews2023

Aerosol pulmonary immune engineering.

Emma R Sudduth, Michael Trautmann-Rodriguez, Nicole Gill, Kartik Bomb, Catherine A Fromen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Rewiring the Lung-CNS Axis After Spinal Cord Injury.Journal of inflammation research · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Nanotechnology of inhalable vaccines for enhancing mucosal immunity.Drug delivery and translational research · 2024
    Review
  15. COPD and Immune Checkpoint Inhibitors for Cancer: A Literature Review.International journal of chronic obstructive pulmonary disease · 2024
    Review
  16. On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI).European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2023
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emma R SudduthDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Michael Trautmann-RodriguezDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Nicole GillDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Kartik BombDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Catherine A FromenDepartment of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA. Electronic address: cfromen@udel.edu.

Funding

Chemistry-Biology Interface Predoctoral Training Grant 2024-2029T32GM133395 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine Leimkuhler Grimes · 2019 to 2026
$3.7M
Multiscale considerations for immune engineering at mucosal interfacesR35GM142866 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine A Fromen · 2021 to 2026
$2.4M
NIGMS NIH HHS R35 GM142866NIGMS NIH HHS T32 GM133395
6 · The paper itself

Abstract

Aerosolization of immunotherapies poses incredible potential for manipulating the local mucosal-specific microenvironment, engaging specialized pulmonary cellular defenders, and accessing mucosal associated lymphoid tissue to redirect systemic adaptive and memory responses. In this review, we breakdown key inhalable immunoengineering strategies for chronic, genetic, and infection-based inflammatory pulmonary disorders, encompassing the historic use of immunomodulatory agents, the transition to biological inspired or derived treatments, and novel approaches of complexing these materials into drug delivery vehicles for enhanced release outcomes. Alongside a brief description of key immune targets, fundamentals of aerosol drug delivery, and preclinical pulmonary models for immune response, we survey recent advances of inhaled immunotherapy platforms, ranging from small molecules and biologics to particulates and cell therapies, as well as prophylactic vaccines. In each section, we address the formulation design constraints for aerosol delivery as well as advantages for each platform in driving desirable immune modifications. Finally, prospects of clinical translation and outlook for inhaled immune engineering are discussed.

Indexed as

LungVaccinesAerosolsDrug Delivery SystemsHumansImmunotherapyAerosolsVaccinesAsthmaBiologicsCancerCOPDCOVID-19Cystic fibrosisImmune engineeringImmunotherapyParticulatesPulmonary deliverySmall molecules

Identifiers

PMID37100206
PMCPMC10527166

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.